Madrigal Pharmaceuticals (MDGL) 今日盘中大跌7.56%，引发市场广泛关注。
消息面上，公司于盘前公布了2026年第二季度财报。尽管当季产品收入达到3.64亿美元，超出市场预期的3.53亿美元，且核心产品Rezdiffra净销售额同比增长71%，但每股亏损1.99美元，较去年同期的1.90美元有所扩大，净亏损达5793.9万美元。营收与患者数量的强劲增长未能掩盖盈利能力边际恶化的隐忧，市场对盈亏改善节奏的分歧导致股价承压。
此前富国银行给予Madrigal跑赢大盘评级，目标价685美元，但短期内亏损扩大使投资者趋于谨慎，盘前跌势延续至盘中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.